About cookies

Cookies help us improve our online service and improve its content and accessibility. Some cookies are necessary for the pages to work properly. You can accept all cookies or only those that are necessary. You can change the settings by clicking Cookie settings.

Cookie settings

Cookie settings

With the help of cookies, we develop our online service and improve its content and accessibility. Some cookies are necessary for the functionality of the pages.

You can enable the cookies you want by checking the boxes below. After making your selections, click Save and Close. The online service works even if you do not allow any necessary cookies. However, some differences may occur.

The necessary cookies are automatically stored on your browser when you use our web service. These cookies are used to ensure that the fimea.fi web service functions as intended.

The web analytics tool Snoobi helps us understand how our customers use the fimea.fi web service and where they come from.

We use the Siteimprove service to monitor the accessibility of pages, the functionality of links and the finding of pages on search engines.

Skip to Content
FI
SV
EN
  • Front page
  • For public
  • Databases and registers
  • Development and HTA
  • Marketing Authorisations
  • Medical devices
  • Pharmaceutical safety and information
  • Pharmacies
  • Supervision
  • Veterinary
  • About us
    • Contact us
    • Coronavirus (COVID-19)
    • Russian attack on Ukraine
    • What's new
      • News archive
      • Brexit
      • EU Presidency 2019
    • Open positions
    • Forms
    • Organisation
    • Publications
    • Fees
    • Estimated processing times
    • Frequently asked questions
    • Data requests
    • Data access authorisations
    • Open data
fimea.fi front page fimea.fi front page

SearchBar

  • page search

  • medicine search

Move to advanced medicine search
Medicine search
Contact Information
FI
SV
EN
About us
  •  fimea.fi
    • For public
      • Fimea’s services to citizens
        • Cooperation with patient associations
      • What is a medicine?
        • Generic substitution
        • Generic products
      • What is a biosimilar?
        • Frequently asked questions about biological drugs and biosimilars
      • What is a food supplement?
      • Safety of medicines
        • Monitoring the safety of medicinal products
        • Adverse reactions
        • Submitting a report on an adverse reaction
        • Medicinal products under additional monitoring
        • Product defects
        • Drug interactions
        • Pharmaceutical injuries
      • Correct use of medicines
        • Ensure the safety of your medication
        • Instructions for the safe use of medicines
        • Monitor the effects of your medication
        • How to store medicines?
        • How should medicines be disposed of?
      • List of medicines
      • Where can I find reliable information about medicines?
        • How can I assess the reliability of drug information?
        • Medicinal product packs
        • Package leaflet
      • How are medicines supplied to users in Finland?
        • What factors affect the availability of medicines?
        • Why might a pharmacy run out of my medicine?
        • Obligatory storing of medicines
        • Exemptions and special permits
      • Ordering medicines online
        • Why is the food supplement I ordered considered to be a medicine?
      • Bringing medicines to Finland
      • What medicines can I bring abroad?
      • Falsified medicines
      • Pain relievers and self-care
      • Medicines and pregnancy
      • Medicines for children
        • Developing better medicines for children
        • Collaboration on medicines education
      • Medication of the elderly
      • Vaccines
      • Influenza
        • Influenza vaccinations
        • Antiviral medication
        • Pandemic
    • Databases and registers
      • FimeaWeb
      • Meds75+
      • Consumption
      • Self-medication products
      • Basic register
        • Plasma-derived products with marketing authorisation
      • Substitutable medicinal products
        • Textfile for databases
        • Criteria used in compiling the list
      • ATC codes
      • Shortages
    • Development and HTA
      • Assessment of pharmacotherapies (HTA)
        • Assessment of hospital-only medicinal products
        • Topic selection
        • Nordic collaboration (FINOSE)
        • Assessment reports (in Finnish)
      • Research
        • Research Network for Rational Pharmacotherapy (RATTI)
      • Medicines information
        • Medicines Information Network
        • High-quality medicines information
      • Interprofessional network
      • Patient advisory board
    • Marketing Authorisations
      • Marketing authorisation application
        • Finland as a Reference Member State in the decentralised procedure (DCP)
        • Finland as a Reference Member State in the Mutual Recognition / Repeat Use Procedure (MRP/RUP)
        • Changing of Reference Member State duties to Finland
        • Finland as a rapporteur in the centralised marketing authorisation procedure (CP)
        • Granted and cancelled marketing authorisations
        • Pending marketing authorisation applications
        • Biological Medicinal Products
        • Orphan drugs
        • Paediatric medicines
        • European Pharmacopoeia
        • Active substance names and standard terms
      • Renewals and variation applications
        • Renewals
        • Variation applications
        • Changes to labelling
        • Transferring a marketing authorisation to a new holder
        • Article 5 classification requests for variation applications
        • OTC application
      • Product Information
        • Summary of product characteristics
        • Package leaflet
        • Package labelling
        • Text templates
        • Braille and package leaflets for the visually impaired
        • Trade names of medicinal products
        • Strength
        • Translating influenza vaccines in Finland
      • Electronic marketing authorisation submissions
        • What's new
        • Instructions for electronic marketing authorisation submissions
        • Special characteristics of the electronic marketing authorisation process for veterinary medicines
      • Cancelling a marketing authorisation or registration and sunset clause
        • Cancelling a marketing authorisation or registration
        • Expiration of marketing authorisations and registrations (sunset clause)
        • Sunset clause - concepts
        • Sunset clause exemption
        • List of expired marketing authorisations and registrations
      • Introduction to market and shortage notifications
      • Parallel import
      • Herbal remedies and medicinal products
        • Herbal medicinal products
        • Traditional herbal medicinal products
        • Homeopathic and anthroposophic preparations
      • Innovation Office
        • Informal Regulatory Guidance
        • Scientific Advice
      • Interchangeable medicinal products
      • Safety features
      • Other permits
        • Exemption
      • Frequently asked questions - marketing authorisations
        • Summary of Product Characteristics is to be available also in Swedish
        • Local representative
    • Medical devices
      • Legislation related to medical devices
      • Placing a medical device on the market
        • Intended purpose and classification
        • General safety and performance requirements
        • Clinical evaluation and clinical investigations
        • Performance evaluation and performance studies of IVD-devices
        • Labelling and instructions for use
        • Conformity assessment
        • CE marking
        • Registrations
        • Certificate of free sale
        • Derogation
      • Special device groups
        • Software
        • Biomaterials
        • Nanomaterials
      • Notifications and applications
      • Operators
        • Importers
        • Distributors
          • Distributors' obligations
          • National language requirements
          • Reporting of incidents
          • Import to Finland of at-home tests
      • Manufacturer's incident reporting procedure
        • Incident report
          • IMDRF codes
      • Eudamed database
        • Operators' obligation to submit a notification
    • Pharmaceutical safety and information
      • Pharmaceutical safety
        • Reporting adverse reactions
      • Special permits
        • How to apply for a special permit
      • Biological medicinal products
        • Advanced Therapy Medicinal Products
      • Biosimilars
        • Biosimilars in Finland
      • Regulation on Medicinal Products for Paediatric Use
        • Paediatric Committee
        • Paediatric Investigation Plan
        • Coordination and communication
        • Rewards and incentives
        • Symbol in the labels of medicinal products
    • Pharmacies
      • Pharmacy licences
        • How to apply for a pharmacy licence
        • How to apply for a subsidiary pharmacy licence
        • Supervision Committee
        • Change of pharmacist situations
      • Pharmacy tax
      • Special permits
        • How to apply for a special permit
        • Temporary special permit products
      • Manufacturing medicinal products
      • Schengen certificates
      • PIC/S GMP Guide
      • Dose-dispensing
    • Supervision
      • Pharmacovigilance
        • ICSR reporting to the EudraVigilance system
        • Pharmacovigilance inspections
        • Product defects
        • Summaries of risk management plans
        • Fimea's Instructions to the National Implementation of the Directive 2010/84/EU
        • Product-specific risk minimisation material
      • Clinical Drug Trials
        • Clinical Trials Regulation & CTIS
        • Trials under the EU Regulation
          • Trial application and modifications
        • Trials under the directive during the transitional period
        • Safety reporting in clinical trials
        • GCP inspections
      • Advertising of medicinal products
      • Classification
        • Principles of classification
        • Classification application
        • List of medicines
        • After classification
        • Private imports of medicinal products
      • Pharmaceutical industry
        • Licenses
          • Local pharmaceutical wholesale license holders
        • Registered brokers of medicinal products
      • Good Laboratory Practice (GLP)
      • Mandatory reserve supplies
        • Reports on quantities to be stocked as mandatory reserve supplies
        • List of products to be stocked as mandatory reserve supplies
        • Application for exemption to maintain lower stock levels
        • Special arrangements for fulfilment of the obligation to maintain mandatory reserve supplies
      • Establishments
        • Supervision of blood activities
        • Supervising tissue establishments
        • Supervision of organ activity
      • Certificates of a Pharmaceutical Product (CPP)
        • Applying for an export certificate
      • Narcotics control
        • Additional information to be submitted with narcotics licence applications
      • Batch-specific control
      • GMP certificates
      • Laboratory of Fimea
        • National and international collaboration
      • Legislation
        • International and EU legislation
        • European Pharmacopoeia
          • National pharmacopoeia documents
          • To users of the Pharmacopoeia
          • CEP Procedure
          • International Non-proprietary Names for Pharmaceutical Substances (INN)
        • National laws
        • Administrative regulations
        • Normative guidelines
        • Other guidelines
      • Biobanks
        • Biobank consent
        • National biobank register
        • Guidance and supervision of biobanks at Fimea
    • Veterinary
      • Marketing authorisation procedures
      • Special permits for compassionate use
        • Applying for special permit
        • FAQ
          • A Questions and answers on how to fill in the form
          • B Questions and answers regarding the technical aspects of permit application
          • C Questions and answers regarding the decision and the processing of the application
          • D Other questions and answers
        • Lists of veterinary medicinal products
      • Adverse effects
      • Consumption of veterinary antimicrobials
        • The European Surveillance of Veterinary Antimicrobial Consumption ESVAC
      • Clinical trials on veterinary medicinal products
        • Immunological products
      • Withdrawal period and MRL
        • What is a withdrawal period?
        • MRL
        • Horses as food-producing animals
      • Private import
    • About us
      • Contact us
        • Change of address
        • Copyright
        • Contact
        • Personnel
        • Secure Mail
      • Coronavirus (COVID-19)
        • Frequently asked questions (COVID-19)
        • Adverse reactions reported on corona vaccines
      • Russian attack on Ukraine
      • What's new
        • News archive
        • Brexit
        • EU Presidency 2019
      • Open positions
      • Forms
      • Organisation
        • Strategy
          • Our goals
          • Strategic framework
        • International representation
        • Fimea committees
      • Publications
      • Fees
      • Estimated processing times
      • Frequently asked questions
        • Clinical drug trials
        • Generic medicines
        • Invoicing
        • Marketing authorisations
          • Summary of Product Characteristics is to be available also in Swedish
        • Narcotics control
        • New EudraVigilance -system
      • Data requests
      • Data access authorisations
      • Open data
  • fimea.fi
  • About us
  • What's new

What's new

Suomeksi ⁄ På svenska

News

18.5.2022 New price list for commercially priced services to be introduced from 1 May 2022

4.4.2022 Language versions of the Medical devices pages updated

17.3.2022 The Medicines Barometer surveyed the burden of medicinal treatment on everyday life

16.3.2022 Miia Turpeinen appointed Director of Fimea's Safety and Effectiveness area of responsibility

16.3.2022 Teemu Laakso appointed Head of Development at Fimea

14.3.2022 Clear guidance on safe medicinal treatment provided to all users of medicines on Finnish National Medicines Day 17 March 2022

2.3.2022 Fimea’s final accounts and annual report for 2021 have been published

28.1.2022 EU-wide database of veterinary medicines opened on 28 January 2022

28.1.2022 EU Veterinary Medicinal Products Regulation becomes applicable on 28 January 2022

27.1.2022 Medicines education learning materials are now available on the Safety in School Sports website

Show all

  • fimea.fi
  • About us
  • What's new
  • Front page
  • For public
  • Databases and registers
  • Development and HTA
  • Marketing Authorisations
  • Medical devices
  • Pharmaceutical safety and information
  • Pharmacies
  • Supervision
  • Veterinary
  • About us
  • Contact us
  • Frequently asked questions
  • Forms
Fimea - Frontpage
  • Twitter
P.O. Box 55, FI-00034 FIMEA, FINLAND
Switchboard: +358 29 522 3341
firstname.lastname@fimea.fi
© Fimea 2022
Ad­min­is­trat­ive sec­tor of the Min­istry of So­cial Af­fairs and Health
The Finnish Medicines Agency Fimea is the national competent authority for regulating pharmaceuticals. As a central administrative agency operating under the Ministry of Social Affairs and Health it promotes the health and safety of the population by regulating medicinal, blood and tissue products, and by developing the pharmaceuticals sector.
  • https://www.stm.fi/ The Ministry of Social Affairs and Health
  • fimea.fi Finnish Medicines Agency Fimea
  • thl.fi National Institute for Health and Welfare
  • ttl.fi Finnish Institute of Occupational Health
  • tyosuojelu.fi Työsuojeluhallinto
  • valvira.fi National Authority for Welfare and Health
  • stuk.fi Radiation and Nuclear Safety Authority Radiation and Nuclear Safety Authority